These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 20153429)

  • 1. Nano-interventions for neurodegenerative disorders.
    Fernandes C; Soni U; Patravale V
    Pharmacol Res; 2010 Aug; 62(2):166-78. PubMed ID: 20153429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nano-enabled delivery systems across the blood-brain barrier.
    Hwang SR; Kim K
    Arch Pharm Res; 2014 Jan; 37(1):24-30. PubMed ID: 24170511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM; Amiji MM
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicine as a non-invasive strategy for drug delivery across the blood brain barrier.
    Tam VH; Sosa C; Liu R; Yao N; Priestley RD
    Int J Pharm; 2016 Dec; 515(1-2):331-342. PubMed ID: 27769885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nano carriers for drug transport across the blood-brain barrier.
    Li X; Tsibouklis J; Weng T; Zhang B; Yin G; Feng G; Cui Y; Savina IN; Mikhalovska LI; Sandeman SR; Howel CA; Mikhalovsky SV
    J Drug Target; 2017 Jan; 25(1):17-28. PubMed ID: 27126681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted drug delivery to central nervous system (CNS) for the treatment of neurodegenerative disorders: trends and advances.
    Goyal K; Koul V; Singh Y; Anand A
    Cent Nerv Syst Agents Med Chem; 2014; 14(1):43-59. PubMed ID: 25360772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for drug delivery to the central nervous system by systemic route.
    Kasinathan N; Jagani HV; Alex AT; Volety SM; Rao JV
    Drug Deliv; 2015 May; 22(3):243-57. PubMed ID: 24471801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle- and liposome-carried drugs: new strategies for active targeting and drug delivery across blood-brain barrier.
    Pinzón-Daza ML; Campia I; Kopecka J; Garzón R; Ghigo D; Riganti C
    Curr Drug Metab; 2013 Jul; 14(6):625-40. PubMed ID: 23869808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transport of drugs across the blood-brain barrier by nanoparticles.
    Wohlfart S; Gelperina S; Kreuter J
    J Control Release; 2012 Jul; 161(2):264-73. PubMed ID: 21872624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of neurodegenerative disorders through the blood-brain barrier using nanocarriers.
    Poovaiah N; Davoudi Z; Peng H; Schlichtmann B; Mallapragada S; Narasimhan B; Wang Q
    Nanoscale; 2018 Sep; 10(36):16962-16983. PubMed ID: 30182106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticles for Targeted Brain Drug Delivery: What Do We Know?
    Pinheiro RGR; Coutinho AJ; Pinheiro M; Neves AR
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theranostic applications of nanoparticles in neurodegenerative disorders.
    Ramanathan S; Archunan G; Sivakumar M; Tamil Selvan S; Fred AL; Kumar S; Gulyás B; Padmanabhan P
    Int J Nanomedicine; 2018; 13():5561-5576. PubMed ID: 30271147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting central nervous system pathologies with nanomedicines.
    Mizrahy S; Gutkin A; Decuzzi P; Peer D
    J Drug Target; 2019; 27(5-6):542-554. PubMed ID: 30296187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CNS transporters for treatment of neurodegenerative diseases.
    Jedlitschky G; Grube M; Mosyagin I; Kroemer HK; Vogelgesang S
    Curr Pharm Des; 2014; 20(10):1523-33. PubMed ID: 23789959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanobiotechnology-based strategies for crossing the blood-brain barrier.
    Jain KK
    Nanomedicine (Lond); 2012 Aug; 7(8):1225-33. PubMed ID: 22931448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular drug delivery: nanomedicine applications.
    Vandervoort J; Ludwig A
    Nanomedicine (Lond); 2007 Feb; 2(1):11-21. PubMed ID: 17716187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C60 fullerene derivatized nanoparticles and their application to therapeutics.
    Lin CM; Lu TY
    Recent Pat Nanotechnol; 2012 Jun; 6(2):105-13. PubMed ID: 22455733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the treatment of neurodegenerative disorders employing nanoparticles.
    Spuch C; Saida O; Navarro C
    Recent Pat Drug Deliv Formul; 2012 Apr; 6(1):2-18. PubMed ID: 22272933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticles for direct nose-to-brain delivery of drugs.
    Mistry A; Stolnik S; Illum L
    Int J Pharm; 2009 Sep; 379(1):146-57. PubMed ID: 19555750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies of Engineering Nanoparticles for Treating Neurodegenerative Disorders.
    Nguyen KT; Pham MN; Vo TV; Duan W; Tran PH; Tran TT
    Curr Drug Metab; 2017; 18(9):786-797. PubMed ID: 28124594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.